Surface Ophthalmics Revenue and Competitors

Location

$36M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Surface Ophthalmics's estimated annual revenue is currently $502.5k per year.(i)
  • Surface Ophthalmics's estimated revenue per employee is $100,500
  • Surface Ophthalmics's total funding is $36M.

Employee Data

  • Surface Ophthalmics has 5 Employees.(i)
  • Surface Ophthalmics grew their employee count by -55% last year.

Surface Ophthalmics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Surface Ophthalmics?

Surface Ophthalmics, Inc. is a pharmaceutical company focused on development and commercialization of innovative therapeutics for ocular diseases. We are striving to solve key patient needs in eye care through leveraging deep expertise, a bold approach, an eye toward efficiency, and a clear, differentiated clinical advantages. Our current drug pipeline consists of three proprietary drug candidates, all utilizing Klarity®, a patented delivery vehicle. We are led by an experienced and proven management team and board of directors with over 80 years of ophthalmology related professional experience.

keywords:N/A

$36M

Total Funding

5

Number of Employees

$502.5k

Revenue (est)

-55%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Surface Ophthalmics News

2022-04-19 - Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022 - Benzinga

an ophthalmic-focused healthcare company, today announced that it will ... being developed by Surface Ophthalmics and Melt Pharmaceuticals.

2022-03-30 - Harrow Health Announces Appointments to Its Board of ...

Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused ... Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow...

2022-03-30 - Olympic Ophthalmics Announces FDA Clearance and ...

Neurostimulation approaches to Ocular Surface Disease have received FDA approvals and have also earned clinical acceptance by patients and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M50%N/A
#2
$1.3M5-29%N/A
#3
$0.4M525%N/A
#4
$0.4M50%N/A
#5
$0.4M50%N/A